An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy (Q36610246)

From Wikidata

Jump to navigation Jump to search

scientific article published on 6 June 2012

Language	Label	Description	Also known as
English	An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy	scientific article published on 6 June 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

immunohistochemistry

1 reference

based on heuristic

inferred from title

5

object named as

Tamara L Lotan

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Angelo M De Marzo

9

object named as

Angelo M De Marzo

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Emmanuel S. Antonarakis

1

object named as

Emmanuel S Antonarakis

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Michael A. Carducci

8

object named as

Michael A Carducci

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

author name string

Daniel Keizman

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Zhe Zhang

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Bora Gurel

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Jessica L Hicks

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Helen L Fedor

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Mario A Eisenberger

10

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

6 June 2012

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

118

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

24

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

6063-6071

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Interobserver Variability in Histologic Evaluation of Radical Prostatectomy Between Central and Local Pathologists: Findings of TAX 3501 Multinational Clinical Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Reflecting on 25 years with MYC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Retracted: An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Defining the role of mTOR in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

The emerging role of the PI3-K-Akt pathway in prostate cancer progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Practical methods for tissue microarray construction.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

30 September 2017

Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

28 June 2018

Relationship between the signal ratios of HER-2/CEP17 and c-MYC/CEP17 and the pathological response of neoadjuvant therapy using docetaxel and trastuzumab in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

28 June 2018

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

28 June 2018

Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

28 June 2018

Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

20 September 2018

Accumulation of nuclear p53 and tumor progression in bladder cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3572534

20 September 2018

PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27689

21 January 2018

The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/22674438

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22674438

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22674438

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/22674438

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22674438

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.27689

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36610246&oldid=2201564607"